Suven Life Sciences Schedules Board Meeting for January 29, 2026 to Approve Q3FY26 Financial Results

1 min read | Published on 22 Jan 2026, 03:04 PM |Updated on 22 Jan 2026, 03:04 PM

Reviewed by

Ashish TScanX News Team

Key Highlights

Suven Life Sciences Limited has scheduled its Board of Directors meeting for January 29, 2026, to consider and approve unaudited financial results for the quarter and nine months ended December 31, 2025. The meeting will be held at the company's registered office in Hyderabad. Trading window restrictions are in effect from January 1, 2026, until 48 hours after results declaration, ensuring compliance with insider trading regulations.

*this image is generated using AI for illustrative purposes only.

Suven Life Sciences Limited has announced a board meeting scheduled for January 29, 2026, to review and approve the company's third-quarter financial performance for FY26. The pharmaceutical company issued the formal notice on January 22, 2026, in compliance with regulatory requirements.

Board Meeting Details

The meeting will be conducted at the company's registered office located at SDE Serene Chambers, 6th Floor, Road No 5, Banjara Hills, Hyderabad–500034. The board will consider and approve the unaudited financial results for both standalone and consolidated operations.

Meeting Parameter:	Details
Date:	January 29, 2026
Venue:	Registered Office, Hyderabad
Purpose:	Q3FY26 Unaudited Financial Results
Reporting Period:	Quarter and nine months ended December 31, 2025

Trading Window Restrictions

In accordance with the company's Prevention of Insider Trading (PIT) Code, Suven Life Sciences has implemented trading restrictions for designated persons and their relatives. The trading window closure became effective from January 1, 2026, and will continue until 48 hours after the declaration of the financial results.

This measure ensures compliance with SEBI regulations regarding insider trading and maintains market integrity during the period leading up to the results announcement.

Regulatory Compliance

The board meeting notice has been issued pursuant to Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has duly informed both the BSE Limited and National Stock Exchange of India Limited about the scheduled meeting.

Shrenik Soni, Company Secretary & Compliance Officer, signed the official notice, ensuring all regulatory protocols are followed for the upcoming financial results disclosure.

Historical Stock Returns for Suven Life Sciences